Pseudoprogression after Axi-cel in Primary Refractory PMBCL following Failed Bridging: Case Report and Management Considerations. (PubMed, Case Rep Oncol) - Oct 16, 2026 - "Despite initially misleading clinical and imaging findings in the context of suboptimal baseline conditions, the patient achieved a durable complete remission and remains disease-free 23 months post-CAR T-cell therapy, with excellent quality of life. This case highlights the critical importance of recognizing immune-mediated flare phenomena to guide clinical decision-making and avoid premature treatment discontinuation or misclassification of therapeutic failure."
Journal • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma
|
|
Marie-Noëlle Kronig; Philip Alan Speicher; Urban Novak
|